DiaSorin S.p.A. (VIE:DIAS)
Austria
· Delayed Price · Currency is EUR | Market Cap | 3.84B |
| Revenue (ttm) | 1.21B |
| Net Income (ttm) | 184.11M |
| Shares Out | n/a |
| EPS (ttm) | 3.41 |
| PE Ratio | 20.86 |
| Forward PE | 16.83 |
| Dividend | 1.20 (1.70%) |
| Ex-Dividend Date | May 19, 2025 |
| Volume | 145 |
| Average Volume | 88 |
| Open | 69.62 |
| Previous Close | 71.12 |
| Day's Range | 69.62 - 70.62 |
| 52-Week Range | 58.60 - 101.40 |
| Beta | n/a |
| RSI | 47.86 |
| Earnings Date | Mar 20, 2026 |
About DiaSorin
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urin... [Read more]
Financial Performance
In 2024, DiaSorin's revenue was 1.19 billion, an increase of 3.24% compared to the previous year's 1.15 billion. Earnings were 188.11 million, an increase of 17.68%.
Financial StatementsNews
Invesco International Small-Mid Company Fund Q3 2025 Portfolio Positioning
Invesco International Small-Mid Company Fund added six new positions and exited 11 positions during the quarter. We are benchmark independent, bottom-up investors, focusing on company fundamentals rat...
DiaSorin: Anticipate A Double-Digit EBITDA Growth Rate
DiaSorin's 2024 revenue grew by 3%, with an underlying increase of 7%, and net profit rose to 188.1M EUR, reflecting a 17% EPS increase. The company generated strong free cash flow of 191M EUR, enabli...
DiaSorin S.p.A. (DSRLF) Q4 2024 Earnings Call Transcript
DiaSorin S.p.A. (OTCPK:DSRLF) Q4 2024 Results Conference Call March 14, 2025 12:30 PM ET Company Participants Carlo Rosa - CEO Piergiorgio Pedron - CFO Conference Call Participants Kavya Deshpande - U...
Italy's DiaSorin ex-Covid revenue in line with guidance
Italian medical diagnostics group DiaSorin on Friday reported a 3% rise in 2024 revenue, citing dampened demand for its products with a milder Flu season compared to the previous year.
Diagnostics group DiaSorin's nine-month adjusted core profit up 6%
Italian medical diagnostics group DiaSorin on Tuesday posted a 6% jump in nine-month adjusted core profit to 292 million euros ($318.46 million) at constant exchange rates, driven by its immunodiagnos...
DiaSorin S.p.A. (DSRLF) Q2 2024 Earnings Call Transcript
DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2024 Earnings Conference Call July 29, 2024 11:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen...
DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript
DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript
Diasorin 2023 revenue drops 14%, in line with guidance; shares fall
Italian medical diagnostic group Diasorin on Friday reported a double-digit drop in revenue for 2023, in line with its revenue guidance for the year, but shares dropped as much as 7.3%.
DiaSorin S.p.A. (DSRLF) Q3 2023 Earnings Call Transcript
DiaSorin S.p.A. (OTCPK:DSRLF) Q3 2023 Earnings Conference Call November 3, 2023 11:30 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Confe...
DiaSorin S.p.A. (DSRLF) Q2 2023 Earnings Call Transcript
DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferenc...
DiaSorin S.p.A. (DSRLF) Q4 2022 Earnings Call Transcript
DiaSorin S.p.A. (OTCPK:DSRLF) Q4 2022 Earnings Conference Call March 27, 2023 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen...
DiaSorin: Overvalued Italian Healthcare Company
DiaSorin S.p.A. is an Italian healthcare company that develops, produces, and sells reagent kits and analyzer instruments mostly used to detect patients' diseases. DiaSorin benefited from the outbreak...
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2022 Results - Earnings Call Transcript
DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2022 Earnings Conference Call August 3, 2022 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen...
DiaSorin's (DSRLF) CEO Carlo Rosa on Q1 2022 Results - Earnings Call Transcript
DiaSorin S.p.A. (OTCPK:DSRLF) Q1 2022 Earnings Conference Call May 6, 2022 11:30 AM ET Company Participants Carlo Rosa – Chief Executive Officer Piergiorgio Pedron – Chief Financial Officer Conference...
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2021 Results - Earnings Call Transcript
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2021 Results - Earnings Call Transcript
Italy's DiaSorin sees 60% plunge in COVID-19 revenue next year
Italian diagnostics firm DiaSorin forecast weaker 2022 sales and a near 60% plunge in COVID-19 revenue, with the rapid rollout of vaccines likely to bring the pandemic under control and crimp demand f...
Italian biotech company DiaSorin says its Covid-19 tests can detect omicron variant
Carlo Rosa, CEO of DiaSorin, tells CNBC that the company's Covid-19 tests can detect the omicron variant and discusses what the impact of the new variant will be on mass testing.
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa On Q3 2021 Results - Earnings Call Transcript
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa On Q3 2021 Results - Earnings Call Transcript
The Vanguard Health Care Fund's Top 5 Trades of the 3rd Quarter
The Vanguard Health Care Fund (Trades, Portfolio) recently released its portfolio updates for the third quarter of 2021, which ended on Sept. 30.
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2021 Results - Earnings Call Transcript
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2021 Results - Earnings Call Transcript
Luminex Corporation Declares Second Quarter Cash Dividend
AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0....
DiaSorin: Surfing The COVID-19 Wave, Culminating In A $1.8 Billion Acquisition Of Luminex
DiaSorin is a world leader in the sale of reagents to laboratories. It converts about 25-30% of its revenue into free cash flow.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Luminex Corp. - LMNX
NEW YORK, April 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class...
LUMINEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Luminex Corporation - LMNX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Luminex Corporat...
INVESTIGATION ALERT: Halper Sadeh LLP Investigates LMNX, NUAN, CADE, GNMK; Shareholders are Encouraged to Contact the Firm
NEW YORK, April 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Luminex Corporation (NASDAQ: LMNX) concerning pote...